By comparing HIV-1 variants from people who became infected at the beginning of the epidemic and from people who have recently contracted the virus, we observed an enhanced resistance of the virus to antibody neutralization over time, accompanied by an increase in the length of the variable loops and in the number of potential N-linked glycosylation sites on the HIV-1 envelope gp120 subunit. The enhanced neutralization resistance of HIV-1 in contemporary seroconverters coincided with the poorer elicitation of neutralizing antibody responses, which may have implications for vaccine desig
AbstractObjectivesHIV is able to continuously adapt to and evade the evolving neutralizing antibody ...
Identifying characteristics of the human immunodeficiency virus type 1 (HIV-1) envelope that are eff...
HIV-1 affects over 34 million people worldwide. Although there is no vaccine, some patients develop ...
We compared the neutralization sensitivity of early/transmitted HIV-1 variants from patients infecte...
A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp1...
Human immunodeficiency virus type 1 (HIV-1) has the ability to adapt to the host environment by esca...
Since 2009, a large panel of broad and potent monoclonal neutralizing antibodies (MoNAbs) against HI...
Analysis of longitudinally obtained HIV-1 env sequences from an individual with reported cross-react...
International audienceWe showed previously that during the HIV/AIDS epidemic, the envelope glycoprot...
Most human immunodeficiency virus type 1 (HIV-1)-infected individuals develop an HIV-specific neutra...
Extending our previous analyses to the most recently described monoclonal broadly neutralizing antib...
BACKGROUND: Induction of broadly neutralizing antibodies, such as the monoclonal antibodies IgGb12, ...
For the development of a neutralizing antibody-based human immunodeficiency virus type 1 (HIV-1) vac...
Understanding the molecular determinants of sensitivity and resistance to neutralizing anti-bodies i...
To study how virus evolution affects neutralization sensitivity and to determine changes that occur ...
AbstractObjectivesHIV is able to continuously adapt to and evade the evolving neutralizing antibody ...
Identifying characteristics of the human immunodeficiency virus type 1 (HIV-1) envelope that are eff...
HIV-1 affects over 34 million people worldwide. Although there is no vaccine, some patients develop ...
We compared the neutralization sensitivity of early/transmitted HIV-1 variants from patients infecte...
A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp1...
Human immunodeficiency virus type 1 (HIV-1) has the ability to adapt to the host environment by esca...
Since 2009, a large panel of broad and potent monoclonal neutralizing antibodies (MoNAbs) against HI...
Analysis of longitudinally obtained HIV-1 env sequences from an individual with reported cross-react...
International audienceWe showed previously that during the HIV/AIDS epidemic, the envelope glycoprot...
Most human immunodeficiency virus type 1 (HIV-1)-infected individuals develop an HIV-specific neutra...
Extending our previous analyses to the most recently described monoclonal broadly neutralizing antib...
BACKGROUND: Induction of broadly neutralizing antibodies, such as the monoclonal antibodies IgGb12, ...
For the development of a neutralizing antibody-based human immunodeficiency virus type 1 (HIV-1) vac...
Understanding the molecular determinants of sensitivity and resistance to neutralizing anti-bodies i...
To study how virus evolution affects neutralization sensitivity and to determine changes that occur ...
AbstractObjectivesHIV is able to continuously adapt to and evade the evolving neutralizing antibody ...
Identifying characteristics of the human immunodeficiency virus type 1 (HIV-1) envelope that are eff...
HIV-1 affects over 34 million people worldwide. Although there is no vaccine, some patients develop ...